MPNs

FDA clears BESREMi Pen, adding a simpler self-injection choice for adults with polycythemia vera on long-term ropeginterferon therapy.

During a live event, Kristen M. Pettit, MD, discussed the potential of using treatment earlier in polycythemia vera to alter the disease course.

Ofirnoflast is a first-in-class oral allosteric modulator of NEK7 that previously received FDA orphan drug designation.

The combo did not, however, meet the coprimary end point of absolute change in total symptom score.

A sneak peek at the heme-onc abstracts at EHA 2026: CLL triplets, frontline menin inhibition, earlier myeloma bispecifics, and post‑JAK myelofibrosis combos poised to shift care.

"DISC-0974 treatment resulted in sustained hepcidin and serum iron, regardless of concomitant JAKi therapy or baseline transfusion requirement,” said Naseema Gangat, MBBS.

During a live event, Firas El Chaer, MD, highlighted pivotal data informing decision making in frontline polycythemia vera.

The results strengthen the evidence base for imetelstat's benefit in this high-risk, post-ruxolitinib myelofibrosis population.

Patients with high-risk myelodysplastic syndrome received the novel anti-IL1RAP antibody nadunolimab combined with azacitidine.

Long-term real-world safety and effectiveness of darbepoetin alfa in MDS-related anemia are consistent with registration trial findings.

Jakafi XR offers bioequivalent alternative to twice-daily formulation; pharmacy availability expected by May 8.

During a Case-Based Roundtable event, Thomas LeBlanc, MD, discussed risk stratification and the latest data regarding luspatercept and imetelstat for lower-risk MDS.

The monoclonal antibody LYT-200 demonstrated promising clinical activity and a favorable safety profile in patients with high-risk myelodysplastic syndrome.

The treatment landscape for high- and low-risk polycythemia vera is shifting with large scale studies such REVEAL and Low-PV changing practice.

New CMML molecular framework links genomic classes and iCPSS scoring to predict outcomes and guide optimal stem cell transplant timing.

The FDA has extended the deadline to review Orca-T for the treatment of myelodsyplastic syndromes and acute leukemias with a PDUFA date of July 6, 2026.

TP53 mutations represent a critical high-risk factor across myeloid diseases, necessitating immediate transplant referral as the only curative option due to the limited durability of current standard therapies such as venetoclax and hypomethylating agents.

The combination of selinexor and ruxolitinib achieved a statistically significant and sustained reduction in spleen volume compared with ruxolitinib alone in patients with JAK inhibitor treatment-naïve myelofibrosis, though symptom improvement was comparable across both arms.

Overcoming ESA-refractory MDS involves greater use of targeted agents based on the patient's molecular profile.

PIM-1 kinase inhibitors in myelofibrosis offer new targets to overcome relapsed and refractory disease.

The FDA has granted a priority review and accepted the NDA for rusfertide in PV.

A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS following transplant.

New research defines distinct therapeutic strategies for the 2 classes of CALR mutations in myelofibrosis, with implications for future patient management and clinical trial design.

Post hoc data suggest Orca-T may boost survival and cut non-relapse mortality after allogeneic stem cell transplant in MDS and leukemias, pending phase 3 validation.